MX2015007753A - Composicion de vacunas para sujetos intactos. - Google Patents

Composicion de vacunas para sujetos intactos.

Info

Publication number
MX2015007753A
MX2015007753A MX2015007753A MX2015007753A MX2015007753A MX 2015007753 A MX2015007753 A MX 2015007753A MX 2015007753 A MX2015007753 A MX 2015007753A MX 2015007753 A MX2015007753 A MX 2015007753A MX 2015007753 A MX2015007753 A MX 2015007753A
Authority
MX
Mexico
Prior art keywords
vaccine
vaccine composition
subjects
naive subjects
directed
Prior art date
Application number
MX2015007753A
Other languages
English (en)
Spanish (es)
Inventor
Hans Arwidsson
Anna-Karin Maltais
Original Assignee
Eurocine Vaccines Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurocine Vaccines Ab filed Critical Eurocine Vaccines Ab
Publication of MX2015007753A publication Critical patent/MX2015007753A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Otolaryngology (AREA)
MX2015007753A 2012-12-17 2013-12-17 Composicion de vacunas para sujetos intactos. MX2015007753A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12197522.1A EP2742952A1 (en) 2012-12-17 2012-12-17 Influenza vaccine composition
PCT/EP2013/077006 WO2014095943A1 (en) 2012-12-17 2013-12-17 Vaccine composition for naive subjects

Publications (1)

Publication Number Publication Date
MX2015007753A true MX2015007753A (es) 2016-01-08

Family

ID=47358019

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015007753A MX2015007753A (es) 2012-12-17 2013-12-17 Composicion de vacunas para sujetos intactos.
MX2015007688A MX2015007688A (es) 2012-12-17 2013-12-17 Composicion de vacunas para uso en poblaciones inmunocomprometidas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2015007688A MX2015007688A (es) 2012-12-17 2013-12-17 Composicion de vacunas para uso en poblaciones inmunocomprometidas.

Country Status (12)

Country Link
US (2) US11065325B2 (enExample)
EP (4) EP2742952A1 (enExample)
JP (3) JP2016502996A (enExample)
KR (3) KR20150132092A (enExample)
CN (3) CN112826929A (enExample)
AU (2) AU2013360890B2 (enExample)
BR (2) BR112015014174A2 (enExample)
CA (2) CA2895028A1 (enExample)
HK (2) HK1213492A1 (enExample)
MX (2) MX2015007753A (enExample)
RU (2) RU2661407C2 (enExample)
WO (2) WO2014095944A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101857839B1 (ko) * 2010-09-30 2018-05-14 유로씨네 백신즈 에이비 개선된 백신 조성물들
EP3197487B1 (en) 2014-09-26 2022-08-03 Seqirus UK Limited Vaccination of immunocompromised subjects
EP4144369A1 (en) * 2014-09-26 2023-03-08 Seqirus UK Limited Vaccination of immunocompromised subjects
RU2634247C2 (ru) * 2015-09-28 2017-10-24 Федеральное государственное бюджетное научное учреждение "СЕВЕРО-КАВКАЗСКИЙ ЗОНАЛЬНЫЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ВЕТЕРИНАРНЫЙ ИНСТИТУТ" (ФГБНУ СКЗНИВИ) Способ стимуляции иммунного ответа и препарат для его осуществления
WO2019108928A1 (en) * 2017-11-30 2019-06-06 Ohio State Innovation Foundation Mucoadhesive nanoparticle entrapped influenza virus vaccine delivery system
CN115551355B (zh) * 2020-04-16 2024-11-12 拜耳公司 活性化合物结合物和包含它们的杀真菌剂组合物
EP4135519B1 (en) * 2020-04-16 2024-09-25 Bayer Aktiengesellschaft Active compound combinations and fungicide compositions comprising those
LT4135520T (lt) * 2020-04-16 2024-12-27 Bayer Aktiengesellschaft Veikliųjų medžiagų deriniai ir juos apimančios fungicidų kompozicijos
CN112063699B (zh) * 2020-09-16 2021-06-18 成都市疾病预防控制中心 一种用于研究hiv感染者免疫衰老机制的系统
EP4463180A2 (en) * 2022-01-10 2024-11-20 The Children's Medical Center Corporation Methods and compositions relating to immunization of immune distinct patients

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9602280D0 (sv) 1996-06-10 1996-06-10 Pharmatrix Ab Immunstimulerande lipidformulering
SE9900496D0 (sv) 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine formulation
US8410248B2 (en) 1999-03-12 2013-04-02 Human Genome Sciences Inc. HWBAO62 polypeptides
EP1372528B1 (en) 2001-04-05 2013-01-02 Novartis Vaccines and Diagnostics, Inc. Mucosal boosting following parenteral priming
US20050208602A1 (en) 2001-08-10 2005-09-22 Rosen Craig A 89 human secreted proteins
WO2004042000A2 (en) 2002-05-17 2004-05-21 Human Genome Sciences, Inc. 157 human secreted proteins
WO2004047862A1 (en) 2002-11-26 2004-06-10 Eurocine Ab Novel amine-based adjuvant
CN1867355A (zh) 2003-08-11 2006-11-22 财团法人阪大微生物病研究会 包含诱导粘膜免疫的佐剂的新型疫苗
CA2609038A1 (en) 2005-05-18 2006-11-23 Trinity Biosystems, Inc. Methods and compositions for immunizing against chlamydia infection
CN103012169B (zh) 2005-06-30 2016-04-20 卫材R&D管理有限公司 用于制备免疫佐剂的化合物
CN101257919B (zh) 2005-08-05 2012-08-29 国立大学法人德岛大学 可以由选择性产生IgA抗体向产生IgA和IgG两种抗体转换的抗原药物载体和使用该载体的经鼻·粘膜疫苗
RU2323742C1 (ru) * 2007-02-15 2008-05-10 Государственное учреждение Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова (ГУ НИИВС им. И.И. Мечникова) Способ повышения иммуногенности инактивированной гриппозной вакцины
WO2009071633A1 (en) 2007-12-06 2009-06-11 Glaxosmithkline Biologicals S.A. Influenza composition
US20090291095A1 (en) 2008-05-23 2009-11-26 The Regents Of The University Of Michigan Nanoemulsion adjuvants
US9415006B2 (en) 2008-05-23 2016-08-16 The Regents Of The University Of Michigan Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same
US20130178383A1 (en) 2008-11-12 2013-07-11 David Spetzler Vesicle isolation methods
WO2010138806A2 (en) 2009-05-28 2010-12-02 Curna, Inc. Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
KR101857839B1 (ko) 2010-09-30 2018-05-14 유로씨네 백신즈 에이비 개선된 백신 조성물들

Also Published As

Publication number Publication date
BR112015014174A2 (pt) 2017-07-11
CN104870010A (zh) 2015-08-26
AU2013360890A1 (en) 2015-07-02
JP2016502997A (ja) 2016-02-01
HK1213492A1 (zh) 2016-07-08
HK1212611A1 (zh) 2016-06-17
CN104884085A (zh) 2015-09-02
EP2931307A1 (en) 2015-10-21
EP2931308B1 (en) 2018-10-10
EP2742952A1 (en) 2014-06-18
AU2013360889A1 (en) 2015-07-02
AU2013360889C1 (en) 2017-06-08
MX2015007688A (es) 2015-09-07
EP3431101A1 (en) 2019-01-23
KR20210007042A (ko) 2021-01-19
CA2895028A1 (en) 2014-06-26
JP2016502996A (ja) 2016-02-01
AU2013360890B2 (en) 2017-04-13
EP2931307B1 (en) 2018-09-12
WO2014095944A1 (en) 2014-06-26
CN112826929A (zh) 2021-05-25
RU2661408C2 (ru) 2018-07-16
BR112015014243A2 (pt) 2017-07-11
RU2015129077A (ru) 2017-01-23
RU2661407C2 (ru) 2018-07-16
US20150306205A1 (en) 2015-10-29
US20150306204A1 (en) 2015-10-29
EP2931308A1 (en) 2015-10-21
BR112015014243A8 (pt) 2019-10-08
WO2014095943A1 (en) 2014-06-26
US11065325B2 (en) 2021-07-20
CA2895023A1 (en) 2014-06-26
JP2019112448A (ja) 2019-07-11
KR20150132092A (ko) 2015-11-25
KR20150132093A (ko) 2015-11-25
RU2015129028A (ru) 2017-01-23
AU2013360889B2 (en) 2016-12-01

Similar Documents

Publication Publication Date Title
MX2015007753A (es) Composicion de vacunas para sujetos intactos.
MX2012009581A (es) Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
MX386142B (es) COMPOSICIONES INMUNOGÉNICAS PARA EL CORONAVIRUS DEL SÍNDROME RESPIRATORIO DE ORIENTE MEDIO (MERS-CoV) Y SUS USOS.
MX383065B (es) Mutantes de virus de influenza y usos para los mismos.
MX2021001053A (es) Vacunas contra virus de la influenza y sus usos.
MX395525B (es) Composiciones inmunogenicas para usar en vacunas neumococicas.
MX2015010880A (es) Combinacion de vacunacion e inhibicion de la trayectoria pd-1.
NZ708922A (en) Nasal influenza vaccine composition
EA201391515A1 (ru) Инактивированная вакцина вируса денге
BR112015008417A8 (pt) composição imunogênica, vacina, e, uso de uma composição imunogênica
PE20151588A1 (es) Vacuna contra el virus del dengue
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
EA201290956A1 (ru) Вакцина против вич
MX2021006021A (es) Procedimiento de disminucion de la inmunogenicidad de proteinas y peptidos.
BR112015021523A8 (pt) composição de uma vacina contra a tosse convulsa acelular, e, usos da composição e de antígenos da bordetella pertussis
CL2012003458A1 (es) Vector que comprende un polipeptido antigénico de campylobacter; composicion farmacéutica que comprende dicho vector; uso del vector para mejorar respuesta inmune del sujeto al polipéptido antigénico.
BR112015002549A2 (pt) regime de vacinação para proteger uma criança contra infecção ou doença causada por vírus sincicial respiratório, composição imunogênica ou pluralidade de composições imunogênicas, uso de uma composição imunogênica ou de uma pluralidade de composições imunogênicas
MX376962B (es) Nuevos compuestos macrociclicos.
EA033027B1 (ru) Ослабленные вакцины от свиного гриппа и способы их получения и применения
MX347911B (es) Vacuna contra virus de diarrea viral de bovinos.
MX363464B (es) Vacunas contra influenza h5.
WO2013173256A3 (en) New and improved influenza vaccines
ES2503516R1 (es) Complejo inmunogénico para vacunación y método de obtención
MX368601B (es) Composicion inmunogenica contra la aeromonas hydrophila.
BR112013023354A2 (pt) vacina para rinite equina